Cantor Fitzgerald Maintains Neutral on Gilead Sciences, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer maintains a Neutral rating on Gilead Sciences (NASDAQ:GILD) but lowers the price target from $75 to $70.
July 22, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer maintains a Neutral rating on Gilead Sciences but lowers the price target from $75 to $70.
The lowered price target from $75 to $70 suggests a less optimistic outlook for Gilead Sciences, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100